Provides relative to Medicaid coverage through the TEFRA option program (EN SEE FISC NOTE GF EX)
Summary
HB 595 amends Louisiana law governing Medicaid coverage under the TEFRA option, which is a pathway that allows certain children with disabilities to qualify for Medicaid based on the level of care they require rather than on household income alone. The bill keeps the existing standard that a child must need a level of care typically provided in a hospital, skilled nursing facility, or intermediate care facility, while recognizing that care outside an institution may still be appropriate.
The bill adds a specific alternative way to satisfy the level-of-care requirement: a child may qualify if, within the previous 12 months, the child has needed emergency hospital care more than once per month and that hospital use is medically necessary to stabilize sickle cell anemia. This creates a targeted eligibility pathway for children with severe sickle cell disease who rely on frequent emergency treatment to manage their condition.
Impact
HB 595 narrows and clarifies TEFRA Medicaid eligibility by adding sickle cell anemia-related emergency hospital use as a qualifying indicator of institutional-level care. In practical terms, it expands access to Medicaid coverage for a specific group of children with severe health needs, and it may increase state Medicaid expenditures and administrative eligibility determinations. The bill amends R.S. 46:977.24(A)(6), affecting the Department of Health’s application of TEFRA criteria and the families of children with serious disabilities or chronic blood disorders.
Sentiment
The voting history suggests broad bipartisan support for the bill. It passed the House with a strong majority, passed the Senate unanimously, and then received overwhelming House concurrence on Senate amendments. The lack of recorded committee transcript discussion limits insight into debate, but the votes indicate general agreement that the measure addresses a serious medical and coverage gap.
Contention
There is little visible opposition in the available record, but the main policy issue is the scope of the eligibility expansion. Supporters appear to favor creating a clearer Medicaid pathway for children with severe sickle cell anemia who repeatedly require emergency stabilization, while any concern would likely center on the fiscal impact to the Medicaid program and whether the new criterion could broaden TEFRA eligibility beyond the traditional institutional-level care standard. The final votes, however, show that any such concerns did not generate significant resistance.